#1 Clinical Trials Search in Europe

Sxr1096

A groundbreaking clinical trial is underway to assess the effectiveness of SXR1096, a new topical cream designed to treat Netherton Syndrome. This rare inflammatory skin condition currently lacks specific treatments, making this study a potential game-changer for patients. The trial aims to evaluate the safety and efficacy of SXR1096 cream compared to a placebo in adults and adolescents with Netherton Syndrome over a four-week treatment period.

Table of Contents

What is SXR1096?

SXR1096 is a new medication being developed to treat Netherton Syndrome, a rare and severe skin condition. It comes in the form of a cream that is applied directly to the skin[1]. This topical treatment is currently being studied in clinical trials to determine if it can help patients with this challenging disease.

Understanding Netherton Syndrome

Netherton Syndrome is an extremely rare and severe form of ichthyosis, which is a group of conditions characterized by dry, thickened, and scaly skin. It is caused by a genetic mutation and is considered a monogenetic disease, meaning it results from changes in a single gene[1]. Currently, there is no specific treatment available for Netherton Syndrome, making the development of SXR1096 particularly important for patients suffering from this condition.

How SXR1096 Works

SXR1096 is designed to target the underlying cause of Netherton Syndrome. It works as a protease inhibitor, which means it blocks the action of certain enzymes in the skin. Specifically, SXR1096 inhibits three proteins called kallikrein 5, 7, and 14 (also known as KLK5, KLK7, and KLK14)[1]. These proteins are found to be overactive in patients with Netherton Syndrome and are believed to contribute to the skin problems associated with the condition.

In healthy individuals, a protein called LEKTI (produced by the SPINK5 gene) normally regulates the activity of these kallikreins in the outer layer of the skin (stratum corneum). However, patients with Netherton Syndrome have a defect in the SPINK5 gene, leading to uncontrolled activity of the kallikreins[1]. By inhibiting these overactive proteins, SXR1096 aims to restore the balance in the skin and potentially improve the symptoms of Netherton Syndrome.

Current Clinical Trial

SXR1096 is currently being studied in a Phase I/II clinical trial. This trial is designed to evaluate both the safety and effectiveness of the cream in patients with Netherton Syndrome. Here are some key points about the study[1]:

  • It is a multicenter study, meaning it is being conducted at multiple medical facilities.
  • The trial is randomized and double-blind, which helps ensure unbiased results.
  • Patients will apply the SXR1096 cream to one area of their skin and a placebo cream (without the active ingredient) to another area for comparison.
  • The treatment period lasts for one month (4 weeks).
  • The study includes both adult and adolescent patients.

Safety and Efficacy Measures

The clinical trial is designed to assess both the safety and effectiveness of SXR1096. The main measures being evaluated include[1]:

  1. Safety: Researchers will monitor the number of patients who experience treatment-related side effects during the 4-week treatment period. This will help determine if SXR1096 is safe to use on the skin.
  2. Efficacy: The effectiveness of SXR1096 will be measured using the Investigator Global Assessment (IGA) score. This score ranges from 0 to 4, with 0 indicating clear skin (no lesions, redness, or scaling) and 4 representing the most severe symptoms. The researchers will compare the change in this score from the beginning to the end of the treatment period.

Additionally, the study will include pharmacokinetic (how the body processes the drug), pharmacodynamic (how the drug affects the body), and biomarker studies to further understand how SXR1096 works in patients with Netherton Syndrome[1].

Potential Benefits of SXR1096

While it’s important to note that SXR1096 is still in the experimental stage, it holds promise for patients with Netherton Syndrome for several reasons:

  • It is specifically designed to target the underlying cause of the condition.
  • As a topical cream, it can be applied directly to the affected skin, potentially minimizing systemic side effects.
  • If proven effective, it could become the first specific treatment for Netherton Syndrome, offering hope to patients who currently have limited treatment options.

However, it’s crucial to remember that more research is needed to confirm the safety and efficacy of SXR1096. The ongoing clinical trial will provide valuable information about this potential new treatment for Netherton Syndrome[1].

Aspect Details
Study Type Phase I/II, multicenter, randomized, double-blind, placebo-controlled
Condition Netherton Syndrome
Intervention SXR1096 cream (active) vs. Placebo cream
Application Twice daily for 4 weeks
Primary Outcomes Safety (adverse events), Efficacy (change in IGA score)
Participants Adults and adolescents with Netherton Syndrome
Mechanism of Action Inhibition of kallikrein 5, 7, and 14 proteases

FAQ

  • What is Netherton Syndrome? Netherton Syndrome is a rare and severe form of ichthyosis, which is a group of genetic skin disorders. It is characterized by inflamed, scaly skin and currently has no specific treatment available.
  • How does SXR1096 cream work? SXR1096 is a specific and potent protease inhibitor that targets kallikrein 5, 7, and 14 – enzymes that are overactive in Netherton Syndrome patients. By inhibiting these enzymes, the cream aims to reduce inflammation and improve skin condition.
  • How is the clinical trial designed? The trial is a Phase I/II, multicenter, randomized, double-blind study. Patients will apply SXR1096 cream to one area of their skin and a placebo cream to another area, allowing each patient to serve as their own control.
  • How long does the treatment last in this trial? Patients will be treated for one month, applying the creams twice daily to predefined areas of their skin.
  • What are the main outcomes being measured in this trial? The trial will primarily assess the safety of SXR1096 by monitoring treatment-related adverse events. It will also evaluate efficacy by measuring changes in the Investigator Global Assessment (IGA) score, which rates the severity of skin lesions.

Ongoing Clinical Trials on Sxr1096

  • Study on the Safety and Effectiveness of SXR1096 Cream for Patients with Netherton Syndrome

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Austria France Germany Sweden

Glossary

  • Netherton Syndrome: A rare, inherited skin disorder characterized by red, scaly skin, brittle hair, and increased susceptibility to allergies and infections.
  • Ichthyosis: A group of genetic skin disorders characterized by dry, thickened, scaly skin.
  • Protease inhibitor: A substance that blocks the action of proteases, which are enzymes that break down proteins.
  • Kallikrein (KLK): A group of enzymes involved in various biological processes, including skin barrier function. In Netherton Syndrome, KLK5, 7, and 14 are overactive.
  • Stratum corneum: The outermost layer of the skin, which acts as a barrier to protect the body from the environment.
  • Pharmacokinetic: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamic: The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • Biomarker: A measurable indicator of a biological state or condition, often used to track the progress of a disease or the effects of treatment.
  • Investigator Global Assessment (IGA): A scale used to evaluate the overall severity of a skin condition, typically ranging from 0 (clear) to 4 (severe).

References

  1. https://clinicaltrials.gov/study/NCT05211830